Name | Number of supported studies | Average coverage | |
---|---|---|---|
GABAergic neuron | 9 studies | 36% ± 18% | |
oligodendrocyte precursor cell | 9 studies | 26% ± 8% | |
glutamatergic neuron | 8 studies | 40% ± 21% | |
interneuron | 6 studies | 41% ± 19% | |
neuron | 5 studies | 29% ± 10% | |
pancreatic A cell | 3 studies | 26% ± 6% | |
granule cell | 3 studies | 26% ± 8% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
brain | 8 studies | 33% ± 17% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
brain | 99% | 731.85 | 2618 / 2642 | 97% | 4.88 | 682 / 705 |
prostate | 99% | 373.10 | 243 / 245 | 87% | 5.56 | 437 / 502 |
pancreas | 93% | 187.81 | 306 / 328 | 73% | 2.09 | 130 / 178 |
uterus | 95% | 218.52 | 161 / 170 | 42% | 1.36 | 192 / 459 |
thymus | 100% | 435.90 | 651 / 653 | 37% | 1.30 | 222 / 605 |
bladder | 90% | 231.24 | 19 / 21 | 41% | 1.55 | 207 / 504 |
esophagus | 83% | 150.76 | 1194 / 1445 | 35% | 0.77 | 64 / 183 |
ovary | 98% | 306.84 | 177 / 180 | 14% | 0.22 | 59 / 430 |
adrenal gland | 52% | 59.98 | 133 / 258 | 59% | 1.93 | 136 / 230 |
lung | 58% | 73.65 | 335 / 578 | 52% | 3.03 | 603 / 1155 |
breast | 83% | 172.03 | 379 / 459 | 24% | 0.37 | 263 / 1118 |
stomach | 84% | 126.07 | 301 / 359 | 18% | 0.43 | 52 / 286 |
intestine | 86% | 142.14 | 829 / 966 | 15% | 0.32 | 77 / 527 |
kidney | 67% | 90.72 | 60 / 89 | 27% | 0.78 | 245 / 901 |
adipose | 90% | 191.65 | 1080 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 88% | 294.16 | 1170 / 1335 | 0% | 0 | 0 / 0 |
spleen | 81% | 106.01 | 195 / 241 | 0% | 0 | 0 / 0 |
skin | 47% | 354.06 | 849 / 1809 | 24% | 0.98 | 113 / 472 |
peripheral blood | 25% | 38.61 | 228 / 929 | 0% | 0 | 0 / 0 |
heart | 24% | 25.93 | 210 / 861 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 22% | 0.67 | 10 / 45 |
liver | 5% | 4.18 | 11 / 226 | 8% | 0.31 | 32 / 406 |
muscle | 6% | 6.23 | 48 / 803 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 3% | 0.04 | 1 / 29 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0001975 | Biological process | response to amphetamine |
GO_0007186 | Biological process | G protein-coupled receptor signaling pathway |
GO_0009968 | Biological process | negative regulation of signal transduction |
GO_0045202 | Cellular component | synapse |
GO_0005886 | Cellular component | plasma membrane |
GO_0043005 | Cellular component | neuron projection |
GO_0005737 | Cellular component | cytoplasm |
GO_0005634 | Cellular component | nucleus |
GO_0005096 | Molecular function | GTPase activator activity |
GO_0005515 | Molecular function | protein binding |
GO_0003924 | Molecular function | GTPase activity |
Gene name | RGS17 |
Protein name | Regulator of G-protein signaling 17 (RGS17) |
Synonyms | RGSZ2 |
Description | FUNCTION: Regulates G protein-coupled receptor signaling cascades, including signaling via muscarinic acetylcholine receptor CHRM2 and dopamine receptor DRD2. Inhibits signal transduction by increasing the GTPase activity of G protein alpha subunits, thereby driving them into their inactive GDP-bound form . Binds selectively to GNAZ and GNAI2 subunits, accelerates their GTPase activity and regulates their signaling activities. Negatively regulates mu-opioid receptor-mediated activation of the G-proteins (By similarity). . |
Accessions | Q9UGC6 ENST00000206262.2 ENST00000367225.6 |